Isthmus Partners LLC Sells 8,326 Shares of Haemonetics Co. (NYSE:HAE)

Isthmus Partners LLC cut its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 17.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 39,770 shares of the medical instruments supplier's stock after selling 8,326 shares during the quarter. Isthmus Partners LLC owned 0.08% of Haemonetics worth $3,197,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of HAE. Thrivent Financial for Lutherans boosted its holdings in Haemonetics by 6,573.6% during the second quarter. Thrivent Financial for Lutherans now owns 849,350 shares of the medical instruments supplier's stock worth $70,267,000 after purchasing an additional 836,623 shares during the last quarter. FMR LLC lifted its position in shares of Haemonetics by 206.3% during the 3rd quarter. FMR LLC now owns 774,529 shares of the medical instruments supplier's stock worth $62,257,000 after buying an additional 521,640 shares in the last quarter. Mizuho Markets Americas LLC purchased a new position in shares of Haemonetics in the 2nd quarter worth approximately $30,080,000. Allspring Global Investments Holdings LLC grew its holdings in shares of Haemonetics by 75.9% in the third quarter. Allspring Global Investments Holdings LLC now owns 795,381 shares of the medical instruments supplier's stock valued at $63,933,000 after acquiring an additional 343,214 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its position in shares of Haemonetics by 327.0% during the second quarter. The Manufacturers Life Insurance Company now owns 307,564 shares of the medical instruments supplier's stock valued at $25,445,000 after acquiring an additional 235,535 shares during the last quarter. Institutional investors own 99.67% of the company's stock.

Haemonetics Stock Performance

Haemonetics stock traded down $0.24 during mid-day trading on Friday, reaching $87.65. The company's stock had a trading volume of 273,618 shares, compared to its average volume of 554,807. The firm's fifty day moving average price is $79.99 and its two-hundred day moving average price is $82.26. The company has a debt-to-equity ratio of 1.39, a quick ratio of 2.09 and a current ratio of 3.49. Haemonetics Co. has a 12-month low of $70.25 and a 12-month high of $97.97. The company has a market capitalization of $4.40 billion, a P/E ratio of 36.37, a PEG ratio of 1.37 and a beta of 0.32.

Haemonetics (NYSE:HAE - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 earnings per share for the quarter, beating the consensus estimate of $1.09 by $0.03. The company had revenue of $345.50 million during the quarter, compared to analysts' expectations of $342.57 million. Haemonetics had a return on equity of 22.67% and a net margin of 9.10%. The firm's quarterly revenue was up 8.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.99 earnings per share. Sell-side analysts predict that Haemonetics Co. will post 4.59 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HAE. Needham & Company LLC restated a "buy" rating and issued a $112.00 price objective on shares of Haemonetics in a research note on Friday, November 15th. Citigroup reduced their price target on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research report on Thursday, August 22nd. Barrington Research reaffirmed an "outperform" rating and issued a $108.00 price objective on shares of Haemonetics in a research report on Friday, November 8th. CL King began coverage on shares of Haemonetics in a research note on Friday, September 13th. They issued a "buy" rating and a $116.00 target price on the stock. Finally, JMP Securities restated a "market outperform" rating and set a $125.00 price target on shares of Haemonetics in a research note on Tuesday, August 13th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Haemonetics currently has an average rating of "Moderate Buy" and an average price target of $107.88.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.